Showing results (11-20 of 333) with videos related to
Sort By:
Pageof 34
Blood Cancer Discovery|October 12, 2023
Potent Personalized Venetoclax Partners for Acute Myeloid Leukemia Identified by Ex Vivo Drug ScreeningPamela S BeckerBlood Cancer Discovery|July 20, 2023
A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AMLLanpeng Chen, Eline Pronk, Claire van Dijk, et al.Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.Blood Cancer Discovery|September 21, 2020
BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC ActivityCharles R Schmidt, Nicholas J Achille, Aravinda Kuntimaddi, et al.Blood Cancer Discovery|September 25, 2020
Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating FunctionsGiovannino Silvestri, Rossana Trotta, Lorenzo Stramucci, et al.Blood Cancer Discovery|September 2, 2022
Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse OutcomesMeghan C Ferrall-Fairbanks, Abhishek Dhawan, Brian Johnson, et al.Blood Cancer Discovery|January 11, 2022
Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer ToxicityM Paulina Velasquez, Stephen GottschalkBlood Cancer Discovery|January 11, 2022
Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsMark Roschewski, Davide Rossi, David M Kurtz, et al.Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.Blood Cancer Discovery|November 15, 2021
Overcoming Acquired Epigenetic Resistance to BTK InhibitorsArthur L Shaffer, James D Phelan, James Q Wang, et al.Pageof 34